Case report highlights potential of repurposed drug for Alzheimer’s disease treatment

Written by Alice Weatherston

A small study carried out at the Human Microbiology Institute (NY, USA) and published recently in the Journal of Medical Case Reports, has revealed a potential new treatment for late-stage Alzheimer’s disease. A team made up of Victor Tetz and George Tetz  (both Human Microbiology Institute) treated a 77 year old Alzheimer’s patient with deoxyribonuclease I, a repurposed medication previously approved by the FDA for the treatment of mucus buildup in cystic fibrosis patients. The patient had been diagnosed with dementia and behavioral disturbance secondary to late-onset Alzheimer’s disease approximately 30 months before the research team first met them and...

To view this content, please register now for access

It's completely free